Shibuya chooses ADVA to deliver encrypted services to Nordic banks
16.2.2023 11:00:00 EET | Business Wire | Press release
ADVA (FSE: ADV) today announced that Shibuya is deploying its open optical technology to deliver secure managed services to leading banks across the Nordics and Baltics. The new network features robust optical encryption cards from Adva Network Security for critical data protection. Shibuya, a leading Swedish IT service provider and ADVA’s long-term Select partner, is using the solution to offer highly available connectivity with end-to-end data protection.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230215005611/en/
ADVA’s technology is helping banks securely transport mission-critical data throughout the Nordic and Baltic regions. (Photo: Business Wire)
“For our financial customers, security couldn’t be more crucial. That’s why we’re ensuring that our managed services protect data in motion with the most robust defense available. At Shibuya, we specialize in delivering secure and sustainable IT environments, and ADVA’s solutions are a perfect fit,” said Jessica Liljefors, business area manager at ShibuyaCare, Shibuya. “Adva Network Security‘s encryption technology and the unique experience of its team help us deliver the strongest possible protection and offer complete peace of mind to our banking clients and their customers. Combined with our extensive cybersecurity measures, local data centers near the customers and 24/7 IT support, we can provide the high-end services demanded by the financial sector.”
The new solution safeguards mission-critical financial traffic using ConnectGuard™ Optical encryption technology provided by Adva Network Security. The technology protects data in-flight to the strictest regulatory requirements with minimal impact on throughput. Part of the new infrastructure is built on the ADVA FSP 3000 TeraFlex™ platform, which uses ultra-flexible modulation with fractional QAM. This supports 600Gbit/s streams while ensuring the lowest possible cost per bit. ADVA’s technology also supports the latest generations of low-latency Fibre Channel, empowering financial network operators to keep up with the requirements of new server and storage technologies – a key consideration for Shibuya and some of its enterprise customers.
“The reputation of today’s financial institutions is built on trust and confidence. By enabling banking customers to harness our TeraFlex™ terminal and enterprise cards, Shibuya is ensuring that Nordic financial enterprises can protect the integrity of highly sensitive data wherever it happens to be in the network. What’s more, our technology delivers the highest levels of performance while also reducing cost per bit,” commented Hartmut Müller-Leitloff, SVP of sales EMEA at ADVA. “And for major banks, being able to utilize the best available storage area network protocols is also key for meeting new business continuity needs and staying operational in the face of any disruption.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com.
About Shibuya
Shibuya creates secure and sustainable IT environments for a digital Sweden. The company is one of the country’s premier operators in business-critical IT and delivers services in, among other things, data center infrastructure and IT operation, hybrid cloud solutions, cyber security, 24/7 IT service and support, communication, application operations and third-party services. Shibuya has strategic partnerships with leading manufacturers and reference solutions with several of the Nordics’ most demanding IT operations in both the private and public sectors. The company is certified according to ISO 14001, 9001 and 27001 standards and is part of the Pulsen Group. www.shibuya.se
Published by:
ADVA Optical Networking SE, Munich, Germany
www.adva.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230215005611/en/
Contact information
For press:
Gareth Spence
t +44 1904 699 358
public-relations@adva.com
For investors:
Stephan Rettenberger
t +49 89 890 665 854
investor-relations@adva.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 15:32:00 EEST | Press release
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company's plans to advance the program globally. The FDA granted RPD Designation based on its determination that A-T is a serious and life-threatening disease that primarily affects individ
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 15:00:00 EEST | Press release
Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT), sensor, and asset data. It helps organizations track and visualize public events, supply chains, and infrastructure to identify and respond to potential threats. ArcGIS Velocity for ArcGIS Enterprise expands cloud-native support to enterprise customers across industries in government and business that rely on firewall protection and internal security compliance. ArcGIS Velocity connects to more than 20 ready-to-use feeds for real-time data providers, including Dataminr, Samsara, Fli
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 15:00:00 EEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 15:00:00 EEST | Press release
Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, umbilical, manifolds, multiphase flowmeters and control systems, along with installation, commissionin
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 13:00:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that it has entered into a securities purchase agreement for a private placement of approximately $85 million in upfront gross proceeds, before the deduction of private placement expenses, and up to an additional $255 million upon the full exercise of purchase warrants. The financing was led by Commodore Capital, with participation from RA Capital Management, TCGX, Invus, and Ligand Pharmaceuticals. The net proceeds of this financing are expected to support Agenus’ strategic prioritization of botensilimab and balstilimab (BOT+BAL) for the neoadjuvant treatment of microsatellite-stable (MSS) colon cancer, including advancement of ROBBIN1, the Company’s planned registrational Phase 3 neoadjuvant trial in microsatellite-stable (MSS) colon cancer. High-risk Stage II and Stage III MSS colon cancer affect an estimated 38,000 patients annually in the US and more than 200,000 patients worldwide,2 representing a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
